Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/rccm.202308-1477LE | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma.
Nat Commun
September 2025
Department of Medicine, University of Washington, Seattle, WA, USA.
Mepolizumab (anti-IL5 therapy) reduces asthma exacerbations in urban children with exacerbation-prone eosinophilic asthma. We previously utilized nasal transcriptomics to identify inflammatory pathways (gene co-expression modules) associated with asthma exacerbations despite this therapy. In this study, we applied differential gene correlation analysis on these targeted gene co-expression modules to gain better insight into the treatment effects on correlation structure within gene networks.
View Article and Find Full Text PDFMepolizumab Reduces Inflammatory Eosinophils in Nasal Polyp Tissue and Restores Histological Alterations.
J Investig Allergol Clin Immunol
July 2025
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Background And Objectives: Eosinophilic inflammation and IL-5 are key therapeutic targets in type 2 chronic rhinosinusitis with nasal polyposis (CRSwNP). Based on surface expression of CD62L, 2 eosinophil subpopulations, homeostatic and inflammatory, were recently described. Objectives: First, we aimed to investigate the association between these subpopulations and the severity of CRSwNP, and second, to analyze the impact of mepolizumab on tissue eosinophil subpopulations.
View Article and Find Full Text PDFMepolizumab-induced Changes in Nasal Methylome and Transcriptome to Predict Response in Asthma.
Am J Respir Crit Care Med
May 2024
Centre for Respiratory Research, National Institute for Health Research Nottingham, Biomedical Research Centre, School of Medicine, Nottingham, United Kingdom.
Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report.
BMC Neurol
August 2022
Department of Neurology, University of Minnesota, 516 Delaware St SE, Minneapolis, MN, 55455, USA.
Background: Posterior Reversible Encephalopathy Syndrome (PRES) is a neurotoxic state characterized by seizures, headache, vision change, paresis, and altered mental status. PRES has an important place in medicine due to the wide variety of causative diseases, infections, and medications that precipitate its mysterious onset. Although exposure to medications, particularly immunosuppressants, cancer chemotherapy, and biologic drugs, is a common occurrence in patients who develop PRES, Mepolizumab has never before been associated.
View Article and Find Full Text PDF